Gastric intestinal metaplasia is associated with gastric dysplasia but is inversely correlated with esophageal dysplasia

Table 1 Patient characteristics and their associations with gastric intestinal metaplasia

	Gastric IM (+)	Gastric IM (-)	Univariate analysis	Multivariate analysis
	n = 468	n = 171		[OR (95%CI)]
Age (mean/median, yr)	61.0/64.0	48.8/53.0	P < 0.001	--
Male sex	208 (44.4%)	77 (45.0%)	P = 0.928	--
Family history of gastric cancer	23 (5.7%)1	5 (2.9%)	P = 0.557	1.38 (0.52, 4.25), P = 0.555
Tobacco use	214 (48.6%)2	61 (36.5%)3	P = 0.007	1.73 (1.18, 2.55), P = 0.005
Alcohol use	100 (22.7%)2	46 (26.9%)	P = 0.219	0.76 (0.50, 1.16), P = 0.199
H2-blocker use	21 (5.1%)4	13 (7.6%)	P = 0.251	0.74 (0.35, 1.59), P = 0.426
PPI use	258 (62.6%)4	94 (55.6%)	P = 0.088	1.23 (0.84, 1.79), P = 0.282
Medicare	245 (52.4%)	46 (26.9%)	P < 0.001	1.94 (1.20, 3.17), P = 0.007
Medicaid	24 (5.1%)	27 (15.8%)	P = 0.003	0.57 (0.30, 1.09), P = 0.090
Private insurance	118 (25.2%)	72 (42.1%)	P < 0.001	0.66 (0.44, 0.99), P = 0.047
Uninsured	68 (14.5%)	32 (18.7%)	P = 0.885	1.04 (0.64, 1.71), P = 0.885

¹Information about family history was missing from 65 patients who had gastric intestinal metaplasia;

²Information about social history was missing from 28 patients who had gastric intestinal metaplasia;

³Information about tobacco use was missing from 4 patients who did not have gastric intestinal metaplasia;

⁴Information about H2-blocker and/or PPI use was missing from 56 patients who had gastric intestinal metaplasia. IM: Intestinal metaplasia; PPI: Proton-pump inhibitor.